CAM
ALXN

CG Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

CG Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,750
Closed -$460K – 153
2016
Q3 		$460K Buy
3,750
+300
+9% +$38.6K 0.17% 100
2016
Q2 		$403K Sell
3,450
-1,600
-32% -$227K 0.16% 95
2016
Q1 		$703K Sell
5,050
-1,700
-25% -$250K 0.28% 79
2015
Q4 		$1.29M Buy
6,750
+1,100
+19% +$192K 0.51% 59
2015
Q3 		$884K Sell
5,650
-1,800
-24% -$328K 0.37% 67
2015
Q2 		$1.35M Sell
7,450
-14,150
-66% -$2.44M 0.51% 57
2015
Q1 		$3.74M Buy
21,600
+360
+2% +$65.2K 1.46% 22
2014
Q4 		$3.93M Buy
21,240
+13,465
+173% +$2.5M 1.55% 24
2014
Q3 		$1.29M Buy
7,775
+3,925
+102% +$645K 0.53% 61
2014
Q2 		$602K Buy
3,850
+500
+15% +$79K 0.25% 84
2014
Q1 		$510K Buy
3,350
+300
+10% +$47.7K 0.23% 94
2013
Q4 		$405K Buy
+3,050
New +$366K 0.19% 106

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

CG Asset Management's ALXN Position: Q4 2016 in Review

CG Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 3,750 shares — an estimated $460K sold.

CG Asset Management first reported a position in ALXN in Q4 2013 and held it in 12 quarters. The position peaked at $3.93M in Q4 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • CG Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • CG Asset Management sold 3,750 Alexion Pharmaceuticals shares in Q4 2016, an estimated $460K.
  • CG Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 12 quarters.
  • CG Asset Management's Alexion Pharmaceuticals position peaked at $3.93M in Q4 2014.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on CG Asset Management's 13F filing for Q4 2016, filed 10 Feb 2017.